Raltegravir pharmacokinetics in treatment-naive patients is not influenced by race: Results from the raltegravir early therapy in african-americans living with HIV (REAL) Study

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 2, 2013, Pages 784-788

  Wohl, David A ^a   Dumond, Julie B ^a   Blevins, Suzanne ^a   Pittard, Donna ^a   Ragan, David ^a   Wang, Ruili ^a   Massengale, Kelley ^a   Walsh, Kendall ^a   Floris Moore, Michelle ^a   Eron, Joseph J ^a   Richardson, Amy ^a   Hudgens, Michael G ^a   Kashuba, Angela D M ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE; RALTEGRAVIR; TENOFOVIR; VIRUS RNA;

ADULT; AFRICAN AMERICAN; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CAUCASIAN; CD4 LYMPHOCYTE COUNT; DOSAGE SCHEDULE COMPARISON; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TIME TO MAXIMUM PLASMA CONCENTRATION;

ADENINE; ADULT; AFRICAN AMERICANS; BODY MASS INDEX; CD4 LYMPHOCYTE COUNT; CONTINENTAL POPULATION GROUPS; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HIV INFECTIONS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; PYRROLIDINONES; VIRAL LOAD;

EID: 84872859169     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01826-12     Document Type: Article

References (25)

1. Bogart LM, Wagner GJ, Galvan FH, Klein DJ. 2010. Longitudinal relationships between antiretroviral treatment adherence and discrimination due to HIV serostatus, race, and sexual orientation among African-American men with HIV. Ann. Behav. Med. 40:184-190.
2. Weintrob AC, Grandits GA, Agan BK, Ganesan A, Landrum ML, Crum-Cianflone NF, Johnson EN, Ordónez CE, Wortmann GW, Marconi VC, IDCRP HIV Working Group. 2009. Virologic response differences between African Americans and European Americans initiating highly active antiretroviral therapy with equal access to care. J. Acquir. Immune Defic. Syndr. 52:574-580.
3. Anastos K, Schneider MF, Gange SJ, Minkoff H, Greenblatt RM, Feldman J, Levine A, Delapenha R, Cohen M. 2005. The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy in women. J. Acquir. Immune Defic. Syndr. 39:537-544.
4. Hartzell JD, Spooner K, Howard R, Wegner S, Wortmann G. 2007. Race and mental health diagnosis are risk factors for highly active antiretroviral therapy failure in a military cohort despite equal access to care. J. Acquir. Immune Defic. Syndr. 44:411-416.
5. Pence BW, Ostermann J, Kumar V, Whetten K, Thielman N, Mugavero MJ. 2008. The influence of psychosocial characteristics and race/ethnicity on the use, duration, and success of antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 47:194-201.
6. McGinnis KA, Fine MJ, Sharma RK, Skanderson M, Wagner JH, Rodriguez-Barradas MC, Rabeneck L, Justice AC. 2003. Understanding racial disparities in HIV using data from the veterans aging cohort 3-site study and VA administrative data. Am. J. Public Health 93:1728-1733.
7. Smith K, Tierney C, Daar E, Mollan K, Budhathoki C, Sax P, Katzenstein D, Godfrey C, Fischl M, Collier A, ACTG A5202 Study Team. 2011. Association of race/ethnicity and sex on outcomes in ACTG Study A5202, abstr. 536. 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA.
8. Johnson MO, Catz SL, Remien RH, Rotheram-Borus MJ, Morin SF, Charlebois E, Gore-Felton C, Goldsten RB, Wolfe H, Lightfoot M, Chesney MA. 2003. Theory-guided empirically supported avenues for intervention on HIV medication nonadherence: Findings from the Healthy Living Project. AIDS Patient Care STDS 17:645-656.
9. Bogart LM, Bird ST, Walt LC, Delahanty DL, Figler JL. 2004. Association of stereotypes about physicians to health care satisfaction, helpseeking behavior, and adherence to treatment. Soc. Sci. Med. 58:1049-1058.
10. Kleeberger CA, Buechner J, Palella F, Detels R, Riddler S, Godfrey R, Jacobson LP. 2004. Changes in adherence to highly active antiretroviral therapy medications in the Multicenter AIDS Cohort Study. AIDS 18: 683-688.
11. Halkitis PN, Parsons JT, Wolitski RJ, Remien RH. 2003. Characteristics of HIV antiretroviral treatments, access, and adherence in an ethnically diverse sample of men who have sex with men. AIDS Care 15:89-102.
12. Schackman BR, Ribaudo HJ, Krambrink A, Hughes V, Kuritzkes DR, Gulick RM. 2007. Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimes for initial HIV therapy: Results of ACTG A5095. J. Acquir. Immune Defic. Syndr. 46:547-554.
13. Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM, Clifford DB, Hulgan T, Marzolini C, Acosta EP. 2004. Pharmacogenetics of efavirenz and central nervous system side effects: An Adult AIDS Clinical Trials Group Study. AIDS 18:2391-2400.
14. Haas DW, Smeaton LM, Shafer RW, Robbins GK, Morse GD, Labbe L, Wilkinson GR, Clifford DB, D'Aquila RT, De Gruttola V, Pollard RB, Merigan TC, Hirsch MS, George AL, Jr, Donahue JP, Kim RB. 2005. Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: An Adult AIDS Clinical Trials Group study. J. Infect. Dis. 192:1931-1942.
15. Ribaudo HJ, Liu H, Schwab M, Schaeffeler E, Eichelbaum M, Motsinger-Reif AA, Ritchie MD, Zanger UM, Acosta EP, Morse GD, Gulick RM, Robbins GK, Clifford D, Haas DW. 2010. Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: An AIDS Clinical Trials Group study. J. Infect. Dis. 202:717-722.
16. Panel on Antiretroviral Guidelines for Adults and Adolescents. 2009. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. U.S. Department of Health and Human Services, Washington, DC.
17. Wenning L, Nguyen B-Y, Sun X, Hwang E, Chen Y, Teppler H, Harvey C, Rhodes R, Ryan D, Azrolan N, Stone J. 2008. Pharmacokinetic/ pharmacodynamics (PK/PD) analyses for raltegravir (RAL) in phase II and 3 studies in treatment experienced HIV-infected patients, abstr 021. Abstr. 9th Int. Wksp. Clin. Pharmacol. HIV Ther., New Orleans, LA.
18. Merck & Co. 2011. Isentress (raltegravir): Full U.S. prescribing information. Merck & Co., Whitehouse Station, NJ.
19. Brainard DM, Wenning LA, Stone JA, Wagner JA, Iwamoto M. 2011. Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor. J. Clin. Pharmacol. 51:1376-1402.
20. Eron JJ, JR, Rockstroh JK, Reynes J, Andrade-Villanueva J, Ramalho-Madruga JV, Bekker LG, Young B, Katlama C, Gatell-Artigas JM, Arribas JR, Nelson M, Campbell H, Zhao J, Rodgers AJ, Rizk ML, Wenning L, Miller MD, Hazuda D, DiNubile MJ, Leavitt R, Isaacs R, Robertson MN, Sklar P, Nguyen BY. 2011. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: A randomized, active-controlled, phase 3 non-inferiority trial. Lancet Infect. Dis. 11:907-915.
21. Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JV, Berger DS, Zhao J, Xu X, Williams-Diaz A, Rodgers AJ, Barnard RJ, Miller MD, DiNubile MJ, Nguyen BY, Leavitt R, Sklar P. 2009. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: A multicentre, double-blind randomised controlled trial. Lancet 374:796-806.
22. Steigbigel RT, Cooper DA, Kumar, et al. 2008. Raltegravir with optimized background therapy for resistant HIV-1 infection. N. Engl. J. Med. 359:339-354.
23. Rezk NL, White N, Kashuba ADM. 2008. An accurate and precise highperformance liquid chromatography method for the rapid quantification of the novel HIV integrase inhibitor raltegravir in human blood plasma after solid phase extraction. Anal. Chim. Acta 628:204-213.
24. Hall HI, Hughes D, Dean HD, Mermin JH, Fenton KA. 2011. HIV Infection-United States, 2005 and 2008. MMWR Surveill. Summ. 60(Suppl):87-89.
25. Moltó J, Valle M, Back D, Cedeno S, Watson V, Liptrott N, Egan D, Miranda C, Barbanoj MJ, Clotet B. 2010. Pharmacokinetics of oncedaily raltegravir (800 mg) in plasma and PBMCs in HIV-infected patients, abstr. LB-01. 11th International Workshop on Clinical Pharmacology of HIV Therapy, Sorrento, Italy. 26. Wang L, Soon GH, Seng KY, Li J, Lee E, Yong EL, Goh BC, Flexner C, Lee L. 2011. Pharmacokinetic modeling of plasma and intracellular concentrations of raltegravir in healthy volunteers. Antimicrob. Agents Chemother. 55:4090-4095.